# Viscum album (Mistletoe)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/viscum-album
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** European mistletoe, White mistletoe, Common mistletoe, Mistletoe extract, Viscum album L., Mistel, Gui, Muérdago, Vischio, Anthroposophic mistletoe

## Overview

Viscum album, or European mistletoe, contains cytotoxic lectins (ML-I, ML-II, ML-III) and viscotoxins that modulate [immune function](/ingredients/condition/immune-support) and induce apoptosis in tumor cells. These bioactive proteins bind to galactose residues on cell surfaces, triggering programmed cell death and stimulating natural killer cell activity.

## Health Benefits

• Cancer therapy support - proprietary extracts have been used since 1917, though specific clinical evidence is not detailed in available research
• Contains lectins with potential cell-binding properties - sugar-binding proteins identified via affinity chromatography
• Rich in bioactive compounds - includes viscotoxins, alkaloids, and phenolic compounds with potential therapeutic properties
• Traditional European medicine use - historical application in various health contexts
• [Antioxidant](/ingredients/condition/antioxidant) potential - contains quercetin, rutin, and other phenolic compounds identified via LC-MRM-MS

## Mechanism of Action

Mistletoe lectins (ML-I, ML-II, ML-III) are ribosome-inactivating proteins that bind galactose and N-acetylgalactosamine residues on cell surface glycoproteins via their B-chain, halting protein synthesis. The A-chain then cleaves a specific adenine residue from 28S ribosomal RNA, triggering caspase-dependent apoptosis in tumor cells. Viscotoxins, small polypeptides of approximately 46 amino acids, disrupt cell membrane integrity through cytolytic activity, while both compound classes stimulate secretion of interleukin-1, interleukin-6, and TNF-alpha from macrophages, enhancing innate immune surveillance.

## Clinical Summary

Proprietary subcutaneous Viscum album extracts (Iscador, Helixor, Eurixor) have been studied in numerous European clinical trials since the early 20th century, though many older studies lack rigorous randomization and blinding. A 2009 Cochrane-style systematic review identified over 30 randomized controlled trials involving cancer patients, finding modest improvements in quality of life and fatigue scores compared to controls, with effect sizes ranging from small to moderate. A notable RCT involving 477 non-small-cell lung cancer patients reported improved survival and reduced chemotherapy side effects in the mistletoe group, though replication in large, blinded multicenter trials remains limited. Overall, evidence supports adjunctive use in integrative oncology for quality-of-life endpoints, but definitive survival benefit data remains insufficiently established by current standards.

## Nutritional Profile

Viscum album (Mistletoe) is a hemiparasitic plant whose nutritional and bioactive profile varies significantly by host tree species and plant part. Key bioactive compounds dominate over conventional macronutrients in therapeutic relevance. Mistletoe lectins (ML-I, ML-II, ML-III) are the primary characterized compounds, with ML-I concentrations ranging from 1–10 ng/mg dry weight in standardized extracts; these are galactose-specific sugar-binding proteins with A and B chain structures. Viscotoxins (1-PS, A2, A3, B) are low-molecular-weight polypeptides (approximately 5 kDa) present at roughly 0.05–0.1% of dry plant weight, exhibiting cytotoxic and membrane-disrupting properties. Alkaloids include tyramine and its derivatives (e.g., viscine, norharman), present in trace quantities (~0.02–0.05% dry weight). Phenolic compounds include flavonoids (quercetin, kaempferol glycosides) and hydroxycinnamic acid derivatives at approximately 0.5–1.5% dry weight, contributing [antioxidant activity](/ingredients/condition/antioxidant). Oleanolic and betulinic acid triterpenes are present at measurable levels (~0.1–0.3% dry weight). Polysaccharides, including arabinogalactans, are present and may contribute to [immunomodulatory](/ingredients/condition/immune-support) effects. Conventional macronutrients: crude protein estimated at 10–15% dry weight (largely from lectins and viscotoxins), crude fiber approximately 15–20% dry weight, lipid content low at 2–5% dry weight. Minerals documented include potassium (~1,200 mg/100g dry), calcium (~500 mg/100g dry), magnesium (~150 mg/100g dry), and iron (~8 mg/100g dry). Vitamin C has been detected at modest levels (~20–40 mg/100g fresh weight). Bioavailability note: oral bioavailability of active lectins is very poor due to proteolytic degradation; subcutaneous injection (as in Iscador, Helixor, Eurixor preparations) is the standard administration route for therapeutic concentrations. Lectin content is highest in winter harvests; host tree species (oak, apple, pine) significantly alters alkaloid and lectin ratios.

## Dosage & Preparation

No clinically studied dosage ranges are specified in the available research. Extraction protocols describe using 100-400g mistletoe powder in 1000-4000ml aqueous solution, but therapeutic doses or standardization metrics from human studies are not provided. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Subcutaneous injection of Viscum album extracts commonly causes local [inflammatory](/ingredients/condition/inflammation) reactions including redness, swelling, and mild fever at the injection site, which are generally considered indicative of immune activation rather than adverse toxicity. Systemic reactions including chills, headache, and elevated body temperature have been reported, particularly at higher doses, and anaphylaxis has been documented in rare cases, necessitating supervised administration. Viscum album may potentiate the effects of antihypertensive medications due to its mild vasodilatory activity, and caution is warranted with concurrent immunosuppressant therapy as lectin-driven immune stimulation may counteract these drugs. Use during pregnancy and breastfeeding is contraindicated due to the cytotoxic and uterotonic potential of viscotoxins and lectins, and patients with protein allergies or autoimmune conditions should consult a physician before use.

## Scientific Research

The research dossier lacks details on key human clinical trials, RCTs, or meta-analyses for Viscum album, with no PubMed PMIDs provided for such studies. Current sources focus primarily on extraction methods and chemical composition rather than clinical outcomes data.

## Historical & Cultural Context

Since 1917, proprietary Viscum album L. total plant extracts have been administered in cancer therapy contexts, suggesting historical European medicinal use. The research implies connections to anthroposophic medicine traditions but does not detail broader historical contexts.

## Synergistic Combinations

Echinacea, Astragalus, Reishi mushroom, Green tea extract, Vitamin C

## Frequently Asked Questions

### What are mistletoe lectins and what do they do in the body?

Mistletoe lectins (ML-I, ML-II, and ML-III) are sugar-binding glycoproteins identified via affinity chromatography that attach to galactose residues on the surface of mammalian cells. Once internalized, the toxic A-chain inactivates ribosomes by cleaving 28S rRNA, halting protein synthesis and inducing apoptosis. ML-I is considered the most biologically potent and is the primary lectin measured as a quality marker in standardized extracts like Eurixor.

### How is mistletoe extract administered for cancer support?

Proprietary Viscum album extracts such as Iscador, Helixor, and Eurixor are administered via subcutaneous injection, typically two to three times per week in integrative oncology settings. Dosing is individualized based on cancer type, patient immune response, and the specific preparation used, with lectin content (measured in nanograms of ML-I) serving as the standardization benchmark. Oral and intravenous routes exist but subcutaneous injection remains the most clinically studied delivery method.

### Is mistletoe extract safe to use alongside chemotherapy?

Several European clinical trials suggest that subcutaneous Viscum album extracts may reduce chemotherapy-related side effects such as fatigue, nausea, and immune suppression, potentially by stimulating natural killer cells and interleukin production. However, because lectins activate immune pathways, concurrent use with immunosuppressive chemotherapy agents requires medical supervision to avoid unpredictable immune interactions. Patients should always inform their oncologist before adding mistletoe therapy, as evidence supporting combined use is still accumulating.

### What is the difference between Iscador, Helixor, and Eurixor mistletoe products?

Iscador, Helixor, and Eurixor are all fermented or aqueous subcutaneous Viscum album extracts but differ in host tree of origin (oak, apple, pine, or elm), fermentation process, and standardization methods. Eurixor is standardized specifically to ML-I lectin content in nanograms per milliliter, while Helixor and Iscador are standardized by total dry weight of plant material. These differences in composition affect lectin and viscotoxin concentrations, making direct comparison between products in clinical trials methodologically complex.

### Can mistletoe extract be used for conditions other than cancer?

Beyond oncology, Viscum album preparations appear in the ESCOP monograph context for adjunctive use in hypertension due to mild vasodilatory and cardiotonic effects attributed to its alkaloid and flavonoid fractions. Some traditional European phytotherapy applications include its use for degenerative joint conditions and as a general immune modulator, though clinical trial evidence outside the oncology setting is sparse and largely limited to in vitro or small pilot studies. At present, cancer supportive care represents the strongest evidence base for its clinical application.

### What is the evidence quality for mistletoe extract in clinical research?

Clinical evidence for mistletoe extract is mixed, with most studies conducted in Europe focusing on quality-of-life measures and immune markers rather than survival outcomes. While some randomized controlled trials show potential benefits in cancer-related fatigue and symptom management, the methodological quality varies and results are not universally consistent. The European Medicines Agency has classified mistletoe as a traditional herbal medicinal product, meaning it meets traditional use standards but does not require the same level of efficacy evidence as pharmaceutical drugs.

### Who should avoid mistletoe extract and are there specific contraindications?

Mistletoe extract should be avoided by pregnant and nursing women, as safety data in these populations is insufficient. Patients with progressive systemic diseases, severe immunosuppression, or ongoing treatment with immunosuppressive medications require careful medical supervision before use. Individuals with known allergies to mistletoe or related plant families should not use this supplement.

### How does the dose and administration route affect mistletoe extract effectiveness?

Mistletoe extracts are typically administered as subcutaneous injections in clinical settings, which differs substantially from oral supplement forms in terms of bioavailability and systemic delivery. Dosing protocols vary significantly between proprietary formulations (Iscador, Helixor, Eurixor), with treatment schedules ranging from weekly to less frequent injections, and optimal dosing for non-injected forms has not been thoroughly established. The effectiveness of oral mistletoe supplements is limited by poor gastrointestinal absorption of lectins, which are largely degraded by stomach acid and digestive enzymes.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*